In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages O1124-O1127

  Singh, S ^a,b,c   Bouzinbi, N ^d   Chaturvedi, V ^b   Godreuil, S ^d   Kremer, L ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c IFTM UNIVERSITY   (India)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Mycobacterium abscessus; Clofazimine; Cystic fibrosis; Drug susceptibility; Tigecycline

Indexed keywords

MYCOBACTERIUM ABSCESSUS;

ANTIINFECTIVE AGENT; DRUG COMBINATION;

ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84920271269     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12780     Document Type: Article

References (20)

1. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
2. Sassi M, Drancourt M. Genome analysis reveals three genomospecies in Mycobacterium abscessus. BMC Genomics 2014; 15: 359.
3. Cho YJ, Yi H, Chun J et al. The genome sequence of 'Mycobacterium massiliense' strain CIP 108297 suggests the independent taxonomic status of the Mycobacterium abscessus complex at the subspecies level. PLoS ONE 2013; 8: e81560.
4. Adekambi T, Reynaud-Gaubert M, Greub G et al. Amoebal coculture of "Mycobacterium massiliense" sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004; 42: 5493-5501.
5. Adekambi T, Berger P, Raoult D, Drancourt M. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 1: 133-143.
6. Bastian S, Veziris N, Roux AL et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775-781.
7. Roux AL, Catherinot E, Ripoll F et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol 2009; 47: 4124-4128.
8. Esther CR Jr, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005; 40: 39-44.
9. Viana-Niero C, Lima KV, Lopes ML et al. Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol 2008; 46: 850-855.
10. Maurer FP, Bruderer VL, Ritter C, Castelberg C, Bloemberg GV, Bottger EC. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother 2014; 58: 3828-3836.
11. Macheras E, Roux AL, Bastian S et al. Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. J Clin Microbiol 2011; 49: 491-499.
12. Woods GL, Brown-Elliott BA, Conville PS et al. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd edn. M24-A2., Wayne, PA: Clinical and Laboratory Standards Institute, 2011.
13. Broda A, Jebbari H, Beaton K, Mitchell S, Drobniewski F. Comparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom. J Clin Microbiol 2013; 51: 217-223.
14. Lavollay M, Dubee V, Heym B et al. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect 2013; 20: O297-O300.
15. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-298.
16. van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 2012; 56: 6324-6327.
17. Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010; 35: 400-404.
18. Wallace RJ Jr, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother 2014; 69: 1945-1953.
19. Huang CW, Chen JH, Hu ST et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. Int J Antimicrob Agents 2013; 41: 218-223.
20. Bernut A, Le MV, Lesne T, Lutfalla G, Herrmann JL, Kremer L. In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. Antimicrob Agents Chemother 2014; 58: 4054-4063.